UNITY Biotechnology, Inc. to Announce First Quarter 2019 Financial Results
UNITY will not conduct a conference call in conjunction with the financial results press release.
About UNITY
UNITY is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. UNITY's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter.
InvestorsPeter Rahmer prahmer@enduranceadvisors.com MediaCanale Communications Jason Spark 1-619-849-6005 jason@canalecomm.com
Source: Unity Biotechnology, Inc.